Parkinson's Disease
Gordon Research Conference

June 25-30, 2017
Grand Summit Hotel
Newry, ME, USA

20 years of alpha-synuclein in
Parkinson's Disease
September 7-10 2017

Hotel Mare Nostrum
Athens, Greece

About Origenis

Origenis is a leader in small molecule drug discovery with over 15 years of experience in the field. Origenis is a privately owned company based in Martinsried, Germany.

Origenis runs its own patented Drug Discovery platform MOREsystem┬«. The unique platform combines state-of-the-art drug design, patent analysis, chemical synthesis and biological characterization performed in an integrated manner on 20.000 square feet of integrated lab space.

Origenis runs research alliances as well as active in-house programs. Origenis is currently focussing on anti-inflammatory and CNS drugs. Origenis is offering a variety of early out-licensing opportunities.

Origenis offers access to its proprietary patent database Cippix® -